By physician referral or invitation only

LCCC 1950 - Rituximab for Multicentric Castleman Disease in Malawi

This is a research study to find out if a drug called rituximab is safe for the treatment of multicentric Castleman disease in Malawi.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

International (Malawi)

Additional Study Information

Principal Investigator

Matthew Painschab
Medicine- Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lymphoma)

IRB Number

19-3035

ClinicalTrials.gov

NCT04585893

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.